⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186317 | 1.00 | — | — | |
| SCHEMBL20186427 | 1.00 | — | — | |
| SCHEMBL3335647 | 0.87 | POLB (0.48) | — | |
| SCHEMBL1597059 | 0.87 | POLB (0.48) | — | |
| SCHEMBL1597060 | 0.87 | POLB (0.48) | — | |
| Hydrochloric Acid SCHEMBL11896218 | 0.85 | POLB (0.47) | — | |
| SCHEMBL1596883 | 0.85 | POLB (0.42) | — | |
| SCHEMBL2679802 | 0.85 | POLB (0.42) | — | |
| Hydrochloric Acid SCHEMBL11895384 | 0.85 | POLB (0.47) | — | |
| SCHEMBL1596887 | 0.85 | POLB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335369-B | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3917517-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021126693-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |